Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
NUZ
vs
S
S&P/ASX 300
NUZ
Over the past 12 months, NUZ has underperformed S&P/ASX 300, delivering a return of -34% compared to S&P/ASX 300's 2% drop.
Stocks Performance
NUZ vs S&P/ASX 300
Performance Gap
NUZ vs S&P/ASX 300
Performance By Year
NUZ vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Neurizon Therapeutics Ltd
Glance View
Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-10-05. The firm is engaged in advancing treatments for neurodegenerative diseases. The company is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.